Cargando…
Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test()
The analytical performance of a multi-gene diagnostic signature depends on many parameters, including precision, repeatability, reproducibility and intra-tumor heterogeneity. Here we study the analytical performance of the BluePrint 80-gene breast cancer molecular subtyping test through determinatio...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097521/ https://www.ncbi.nlm.nih.gov/pubmed/32208353 http://dx.doi.org/10.1016/j.tranon.2020.100756 |
_version_ | 1783511013758337024 |
---|---|
author | Mittempergher, Lorenza Delahaye, Leonie JMJ Witteveen, Anke T Snel, Mireille HJ Mee, Sammy Chan, Bob Y Dreezen, Christa Besseling, Naomi Luiten, Ernest JT |
author_facet | Mittempergher, Lorenza Delahaye, Leonie JMJ Witteveen, Anke T Snel, Mireille HJ Mee, Sammy Chan, Bob Y Dreezen, Christa Besseling, Naomi Luiten, Ernest JT |
author_sort | Mittempergher, Lorenza |
collection | PubMed |
description | The analytical performance of a multi-gene diagnostic signature depends on many parameters, including precision, repeatability, reproducibility and intra-tumor heterogeneity. Here we study the analytical performance of the BluePrint 80-gene breast cancer molecular subtyping test through determination of these performance characteristics. BluePrint measures the expression of 80 genes that assess functional pathways which determine the intrinsic breast cancer molecular subtypes (i.e. Luminal-type, HER2-type, Basal-type). Knowing a tumor's dominant functional pathway can help allocate effective treatment to appropriate patients. Here we show that BluePrint is a highly precise and highly reproducible test with correlations above 98% based on the generated index and subtype concordance above 99%. Therefore, BluePrint can be used as a robust and reliable tool to identify breast cancer molecular subtypes. |
format | Online Article Text |
id | pubmed-7097521 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Neoplasia Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-70975212020-03-27 Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test() Mittempergher, Lorenza Delahaye, Leonie JMJ Witteveen, Anke T Snel, Mireille HJ Mee, Sammy Chan, Bob Y Dreezen, Christa Besseling, Naomi Luiten, Ernest JT Transl Oncol Original article The analytical performance of a multi-gene diagnostic signature depends on many parameters, including precision, repeatability, reproducibility and intra-tumor heterogeneity. Here we study the analytical performance of the BluePrint 80-gene breast cancer molecular subtyping test through determination of these performance characteristics. BluePrint measures the expression of 80 genes that assess functional pathways which determine the intrinsic breast cancer molecular subtypes (i.e. Luminal-type, HER2-type, Basal-type). Knowing a tumor's dominant functional pathway can help allocate effective treatment to appropriate patients. Here we show that BluePrint is a highly precise and highly reproducible test with correlations above 98% based on the generated index and subtype concordance above 99%. Therefore, BluePrint can be used as a robust and reliable tool to identify breast cancer molecular subtypes. Neoplasia Press 2020-03-21 /pmc/articles/PMC7097521/ /pubmed/32208353 http://dx.doi.org/10.1016/j.tranon.2020.100756 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original article Mittempergher, Lorenza Delahaye, Leonie JMJ Witteveen, Anke T Snel, Mireille HJ Mee, Sammy Chan, Bob Y Dreezen, Christa Besseling, Naomi Luiten, Ernest JT Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test() |
title | Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test() |
title_full | Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test() |
title_fullStr | Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test() |
title_full_unstemmed | Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test() |
title_short | Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test() |
title_sort | performance characteristics of the blueprint® breast cancer diagnostic test() |
topic | Original article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097521/ https://www.ncbi.nlm.nih.gov/pubmed/32208353 http://dx.doi.org/10.1016/j.tranon.2020.100756 |
work_keys_str_mv | AT mittempergherlorenza performancecharacteristicsoftheblueprintbreastcancerdiagnostictest AT delahayeleoniejmj performancecharacteristicsoftheblueprintbreastcancerdiagnostictest AT witteveenanket performancecharacteristicsoftheblueprintbreastcancerdiagnostictest AT snelmireillehj performancecharacteristicsoftheblueprintbreastcancerdiagnostictest AT meesammy performancecharacteristicsoftheblueprintbreastcancerdiagnostictest AT chanboby performancecharacteristicsoftheblueprintbreastcancerdiagnostictest AT dreezenchrista performancecharacteristicsoftheblueprintbreastcancerdiagnostictest AT besselingnaomi performancecharacteristicsoftheblueprintbreastcancerdiagnostictest AT luitenernestjt performancecharacteristicsoftheblueprintbreastcancerdiagnostictest AT performancecharacteristicsoftheblueprintbreastcancerdiagnostictest |